These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 21771637)

  • 1. Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics.
    Kolkhof P; Borden SA
    Mol Cell Endocrinol; 2012 Mar; 350(2):310-7. PubMed ID: 21771637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences.
    Yang J; Young MJ
    Curr Opin Pharmacol; 2016 Apr; 27():78-85. PubMed ID: 26939027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.
    Rogerson FM; Yao Y; Smith BJ; Fuller PJ
    Clin Exp Pharmacol Physiol; 2004 Oct; 31(10):704-9. PubMed ID: 15554912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid receptor antagonists, a class beyond spironolactone--Focus on the special pharmacologic properties of eplerenone.
    Seferovic PM; Pelliccia F; Zivkovic I; Ristic A; Lalic N; Seferovic J; Simeunovic D; Milinkovic I; Rosano G
    Int J Cardiol; 2015 Dec; 200():3-7. PubMed ID: 26404746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eplerenone for the treatment of cardiovascular disorders.
    Watanabe M; Krum H
    Expert Rev Cardiovasc Ther; 2012 Jul; 10(7):831-8. PubMed ID: 22908915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biotransformation of the mineralocorticoid receptor antagonists spironolactone and canrenone by human CYP11B1 and CYP11B2: Characterization of the products and their influence on mineralocorticoid receptor transactivation.
    Schiffer L; Müller AR; Hobler A; Brixius-Anderko S; Zapp J; Hannemann F; Bernhardt R
    J Steroid Biochem Mol Biol; 2016 Oct; 163():68-76. PubMed ID: 27125452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eplerenone: cardiovascular protection.
    Brown NJ
    Circulation; 2003 May; 107(19):2512-8. PubMed ID: 12756192
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
    Sato A
    Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacology of AZD9977: A novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion.
    Bamberg K; Johansson U; Edman K; William-Olsson L; Myhre S; Gunnarsson A; Geschwindner S; Aagaard A; Björnson Granqvist A; Jaisser F; Huang Y; Granberg KL; Jansson-Löfmark R; Hartleib-Geschwindner J
    PLoS One; 2018; 13(2):e0193380. PubMed ID: 29474466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stereochemical requirements for the mineralocorticoid receptor antagonist activity of dihydropyridines.
    Arhancet GB; Woodard SS; Dietz JD; Garland DJ; Wagner GM; Iyanar K; Collins JT; Blinn JR; Numann RE; Hu X; Huang HC
    J Med Chem; 2010 May; 53(10):4300-4. PubMed ID: 20408553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of the Mineralocorticoid Receptor and Mineralocorticoid Receptor-Directed Therapies in Heart Failure.
    Young MJ; Kanki M; Karthigan N; Konstandopoulos P
    Endocrinology; 2021 Nov; 162(11):. PubMed ID: 34050730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Towards selectively modulating mineralocorticoid receptor function: lessons from other systems.
    Baxter JD; Funder JW; Apriletti JW; Webb P
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):151-65. PubMed ID: 15134814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mineralocorticoid receptors in the heart: lessons from cell-selective transgenic animals.
    Young MJ; Rickard AJ
    J Endocrinol; 2015 Jan; 224(1):R1-13. PubMed ID: 25335936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evolution of aldosterone antagonists.
    Garthwaite SM; McMahon EG
    Mol Cell Endocrinol; 2004 Mar; 217(1-2):27-31. PubMed ID: 15134797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury.
    Kolkhof P; Delbeck M; Kretschmer A; Steinke W; Hartmann E; Bärfacker L; Eitner F; Albrecht-Küpper B; Schäfer S
    J Cardiovasc Pharmacol; 2014 Jul; 64(1):69-78. PubMed ID: 24621652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SM-368229, a novel selective and potent non-steroidal mineralocorticoid receptor antagonist with strong urinary Na+ excretion activity.
    Nariai T; Fujita K; Mori M; Katayama S; Hori S; Matsui K
    J Pharmacol Sci; 2011; 115(3):346-53. PubMed ID: 21358118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis.
    Sica DA
    Heart Fail Rev; 2005 Jan; 10(1):23-9. PubMed ID: 15947888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.